Core Viewpoint - The company, Aotai Biology, reported that as of October 31, 2025, the total number of shareholders is 5,665 [1] Summary by Categories - **Company Information** - Aotai Biology has a total of 5,665 shareholders as of the specified date [1]

Meeting Overview - The second extraordinary general meeting of shareholders was held on November 25, 2025, at the company's conference room in Hangzhou, Zhejiang Province [2] - The total share capital as of the meeting's registration date was 79,280,855 shares, with 973,631 shares in the company's repurchase account not entitled to vote [2] Voting and Attendance - The meeting was convened by the board of directors and chaired by Mr. Gao Fei, utilizing a combination of on-site and online voting methods [4] - All five current directors and three current supervisors attended the meeting, along with the board secretary [4] Resolutions Passed - The following resolutions were approved: - Cancellation of the supervisory board and amendments to the Articles of Association [5] - Revisions to various internal management systems, including: - Shareholders' meeting rules - Board meeting rules - Independent director work system - Related party transaction management system - Prevention of related party fund occupation management system - External guarantee management system - External investment management system - Cumulative voting implementation details - Fundraising management measures [6][7] Legal Compliance - The meeting was witnessed by Shanghai Lifeng Law Firm, confirming that the convening, holding, and voting procedures complied with relevant laws and regulations [8]

Core Points - The company announced the election of Mr. Gao Yuecan as the employee representative director of the third board of directors during the second meeting of the third employee representative assembly held on November 25, 2025 [2]

证券代码：688606 证券简称：奥泰生物 公告编号：2025-054 杭州奥泰生物技术股份有限公司 关于完成董事增选的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、选举独立董事的情况 杭州奥泰生物技术股份有限公司（以下简称"公司"）于2025年10月30日召开了 第三届董事会第十七次会议，审议通过了《关于增选第三届董事会独立董事的议案》， 公司董事会同意提名陈善基先生为公司第三届董事会独立董事，任期自股东大会审议 通过之日起至第三届董事会任期届满之日止。具体内容详见公司于2025年10月31日在 上海证券交易所网站（www.sse.com.cn）披露的《关于增选第三届董事会独立董事的 公告》（公告编号：2025-051）。 2025年11月25日，公司召开了2025年第二次临时股东大会，增选陈善基先生为公 司第三届董事会独立董事，任期自本次股东大会审议通过之日起至第三届董事会任期 届满之日止。 二、选举职工董事的情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）和修订后的《杭州 奥泰生物技术股份有限 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2025-055 杭州奥泰生物技术股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （二） 股东大会召开的地点：浙江省杭州市钱塘区下沙街道乔新路 383 号公司 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 66 | | --- | --- | | 普通股股东人数 | 66 | | 2、出席会议的股东所持有的表决权数量 | 52,995,653 | | 普通股股东所持有表决权数量 | 52,995,653 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 67.6766 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 67.6766 | 注：截至本次股东大会股权登记日的总股本为 79,280,855 股；其中公司回购专用 ...

2025 年第二次临时股东大会的法律意见书 致：杭州奥泰生物技术股份有限公司 上海礼丰律师事务所(以下简称"本所")接受杭州奥泰生物技术股份有限公司 (以下简称"公司")的委托，指派本所律师(以下简称"本所律师")根据《中华人民共 和国证券法》《中华人民共和国公司法》《上市公司股东会规则》等法律、法规、 规范性文件(以下统称"法律法规")及《杭州奥泰生物技术股份有限公司章程》(以 下简称"公司章程")的规定就公司 2025 年第二次临时股东大会(以下简称"本次股 东大会")相关事宜出具法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定及法律意 见书出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽 责和诚实信用原则，进行了充分的核查验证，保证法律意见所认定的事实真实、 准确、完整、及时，所发表的结论性意见合法、准确，不存在虚假记载、误导性 陈述或者重大遗漏，并承担相应法律责任。 本所律师已经按照有关法律法规的要求和律师行业公认的道德标准以及勤 勉尽责的精神对公司本次股东大会相关文件及事实进行了审查和验 ...

Core Viewpoint - On November 21, Aotai Bio experienced a decline of 2.99% with a trading volume of 24.0661 million yuan, indicating a potential shift in investor sentiment and market dynamics [1]. Financing Summary - On November 21, Aotai Bio had a financing buy-in amount of 3.1237 million yuan and a financing repayment of 2.8837 million yuan, resulting in a net financing buy of 240,000 yuan [1]. - As of November 21, the total financing and securities lending balance for Aotai Bio was 86.7704 million yuan, which accounts for 1.68% of its circulating market value, indicating a high level of financing activity compared to the past year [1]. - The financing balance of 86.7704 million yuan exceeds the 70th percentile level over the past year, suggesting a relatively high position in terms of financing [1]. Shareholder and Financial Performance Summary - As of October 31, Aotai Bio had 5,665 shareholders, a decrease of 1.29% from the previous period, while the average circulating shares per person increased by 1.31% to 13,994 shares [2]. - For the period from January to September 2025, Aotai Bio reported a revenue of 633 million yuan, reflecting a year-on-year growth of 2.44%, while the net profit attributable to shareholders decreased by 3.91% to 190 million yuan [2]. Dividend and Institutional Holdings Summary - Aotai Bio has distributed a total of 1.28 billion yuan in dividends since its A-share listing, with 955.6 million yuan distributed over the past three years [3]. - As of September 30, 2025, among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 2.1873 million shares, a decrease of 387,400 shares from the previous period, while Guotai Junan Value Advantage Flexible Allocation Mixed A (000362) entered the top ten as the ninth largest shareholder with 713,300 shares [3].

Core Viewpoint - The discussion at the Shanghai Securities Exchange International Investors Conference highlighted the potential for world-class pharmaceutical companies to emerge from China, driven by innovation, supportive policies, and collaborative teams [1][3]. Group 1: Industry Opportunities - High Fei, Chairman and General Manager of Hangzhou Aotai Biotechnology Co., believes that world-class enterprises will definitely emerge in China, emphasizing the importance of industry opportunities, international environment, and continuous innovation [3]. - Xiao Zhihua, Chairman of Shanghai Aopumai Biotechnology Co., pointed out that while challenges exist for Chinese companies to become truly global in a time of globalization retreat, he remains confident that world-class enterprises will emerge [3]. Group 2: Importance of Policy and Market - Zhang Lianshan, Global R&D President of Jiangsu Hengrui Medicine Co., stressed the significance of confidence and policy support, stating that biopharmaceutical companies must first establish value in the Chinese market to generate global value [3]. - The discussion concluded that with improved innovation capabilities and ongoing policy enhancements, the Chinese pharmaceutical industry is likely to nurture world-class enterprises in the future [3].

杭州奥泰生物技术股份有限公司 2025 年第二次临时股东大会会议资料 杭州奥泰生物技术股份有限公司 2025年第二次临时股东大会会议资料 股票代码：688606 股票简称：奥泰生物 2025 年 11 月 杭州奥泰生物技术股份有限公司 2025 年第二次临时股东大会会议资料 目 录 | 2025 | 年第二次临时股东大会会议须知 | 1 | | --- | --- | --- | | 2025 | 年第二次临时股东大会会议议程 | 3 | | 2025 | 年第二次临时股东大会会议议案 | 5 | | 议案一 | 关于取消监事会、修订《公司章程》并办理工商变更登记的议案 | 5 | | 议案二 | 关于修订公司部分内部管理制度的议案 | 6 | | 议案三 | 关于增选第三届董事会独立董事的议案 | 7 | 五、要求发言的股东及股东代理人，应当按照会议的议程，经会议主持人许可 方可发言。有多名股东及股东代理人同时要求发言时，先举手者发言；不能确定先 后时，由主持人指定发言者。会议进行中只接受股东及股东代理人发言或提问。股 东及股东代理人发言或提问应围绕本次会议议题进行，简明扼要，时间原则上不超 过5分钟。 六 ...

Group 1: Conference Insights - The Shanghai Stock Exchange International Investor Conference highlighted the attractiveness of Chinese asset valuations and significant investment value across three main directions [1] - The conference featured discussions on new opportunities in AI, pharmaceuticals, energy, and high-end manufacturing [1] Group 2: Market Developments - The Shanghai Stock Exchange's Vice President Fu Hao emphasized that the Sci-Tech Innovation Board has strong international characteristics and is evolving into an international market, with increasing foreign participation and a focus on communication with international investors [2] - 360's CFO Zhang Hailong stated that the company aims to enhance safety in the AI world and is fully committed to the "ALL IN AGENT" strategy, positioning itself as a leading digital security enterprise [3] Group 3: Medical Device and Pharmaceutical Industry - Aotai Bio's CEO Gao Fei argued that the strength of a world-class medical device company lies in its niche capabilities rather than sheer size, emphasizing the importance of intellectual property, innovation, and product quality [4] - Optum's Chairman Xiao Zhihua stressed the need for Chinese companies to carve out unique paths to internationalization, focusing on quality and innovation to gain market recognition [4] - Heng Rui Pharma's Global R&D President Zhang Lianshan noted that a truly international pharmaceutical company should achieve $1 to $2 billion in overseas sales from innovative drugs within 15 years [5] Group 4: AI and Robotics - Green Harmonic's CEO Zhang Yuwen highlighted that robots are becoming crucial carriers for AI, requiring deep integration with AI to serve human society effectively [6] - Optum's Deputy General Manager Xu Xueliang discussed how AI is reshaping industrial manufacturing logic, with 2025 seen as a pivotal year for this transformation [7] - Guodian NARI's Secretary Hu Shunjing pointed out that the synergy between vision and brain is key to industrial intelligence, with AI driving advancements in machine vision [8]